P

Pacira Pharmaceuticals

1000 employees

Pacira Pharmaceuticals is a specialty pharmaceutical company dedicated to postsurgical innovation.

Investor insights

Sectors invested in

Biotechnology9
Medical6
Pharmaceutical5
Health Care5
biotechnology3
Biopharma2
Developer Tools2
gene therapy2
osteoarthritis2
musculoskeletal disease2
drug development2
human medicine2
animal health2
Genetics1
Therapeutics1
Life Science1
Software1
Information Technology1
Plastic Surgery1
Medical Device1

Funding rounds participated in

$8.5M sweet spot round size

Most of their 10 investments are in rounds between $3M and $13M

Basic info

Sectors

Biotechnology
Pharmaceutical
Health Care

Date founded

1989

Investments made

S

Spine BioPharma raised $13M on February 8, 2023

Investors: Cercano Management, Viscogliosi Bros., LLC and Pacira Pharmaceuticals

C

CarthroniX raised $2.3M on April 11, 2022

Investors: Pacira Pharmaceuticals

S

Spine BioPharma raised $13M on March 28, 2022

Investors: Cercano Management, Viscogliosi Bros., LLC and Pacira Pharmaceuticals

G

Genascence Corporation raised $11M on January 7, 2022

Investors: Personnel Administrative Svcs, FAN Fund and Pacira Pharmaceuticals

C

CODA Biotherapeutics raised $28M on December 2, 2021

Investors: MPM Capital, Versant Ventures and Pacira Pharmaceuticals

S

Spine BioPharma raised $3M on April 20, 2021

Investors: Pacira Pharmaceuticals

G

GeneQuine Biotherapeutics raised $3.4M on February 15, 2021

Investors: Pacira Pharmaceuticals

G

GeneQuine Biotherapeutics raised $6.5M on February 15, 2021

Investors: High-Tech Gründerfonds, - and Pacira Pharmaceuticals

A

Avalon AI raised $1.5M on August 28, 2020

Investors: Pacira Pharmaceuticals

T

TELA Bio raised $25M on October 30, 2017

Investors: Signet Healthcare Partners, OrbiMed Advisors and Pacira Pharmaceuticals

Funding rounds raised

Total raised

$85M

from 4 investors over 4 rounds

P

Pacira Pharmaceuticals raised $28M on May 3, 2012

Investors: Oxford Finance LLC

P

Pacira Pharmaceuticals raised $85M on November 17, 2008

Investors: MPM Capital, Sanderling Ventures and OrbiMed Advisors

FAQ